The biopharma industry racked up two more IPOs this week, with the monster deal for pharma services firm Quintiles ($Q) and public debut of MS drug developer Receptos ($RCPT). And more than two dozen life sciences companies, the Boston Globe reports, could go public this year--the biggest wave since 2007. The recession has put a damper on IPOs, but upbeat financial markets could mean that more companies might soon go public. Story